Massive liver involvement in a patient with multiple myeloma during thalidomide treatment

Research output: Contribution to journalArticle


The activity of thalidomide in patients with relapsed or refractory multiple myeloma has been well confirmed. However, plasmacytomas were less responsive to thalidomide and extramedullary progression despite serological response has been observed. We described a case of massive liver involvement in a patient treated with thalidomide; we suggest that extramedullary progression could due to a clone selection induced by treatment.

Original languageEnglish
Pages (from-to)230-232
Number of pages3
Issue number2
Publication statusPublished - Apr 2003



  • Extramedullary progression
  • Multiple myeloma
  • Thalidomide

ASJC Scopus subject areas

  • Hematology

Cite this